{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Non-Small+Cell+Carcinoma&page=20", "query": { "condition": "Lung Non-Small Cell Carcinoma", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 3652, "total_pages": 366, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Non-Small+Cell+Carcinoma&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Non-Small+Cell+Carcinoma&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T10:52:35.433Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03752398", "title": "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Excluding Uveal Melanoma)", "Cervical Carcinoma", "Pancreatic Carcinoma", "Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Cancer", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced Solid Tumors", "Undifferentiated Pleomorphic Sarcoma" ], "interventions": [ { "name": "XmAb®23104", "type": "BIOLOGICAL" }, { "name": "Yervoy® (ipilimumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2019-05-01", "completion_date": "2024-02-15", "has_results": false, "last_update_posted_date": "2024-07-05", "last_synced_at": "2026-10-15T10:52:35.433Z", "location_count": 18, "location_summary": "San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03752398" }, { "nct_id": "NCT02650635", "title": "TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Melanoma of the Skin", "Recurrent Non-Small Cell Lung Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Renal Cell Carcinoma", "Solid Neoplasm", "Stage IV Breast Cancer", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Colorectal Cancer", "Stage IVA Pancreatic Cancer", "Stage IVB Colorectal Cancer", "Stage IVB Pancreatic Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "TLR8 Agonist VTX-2337", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-02-05", "completion_date": "2017-06-01", "has_results": false, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-10-15T10:52:35.433Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650635" }, { "nct_id": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Colorectal Cancer", "Breast Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Head and Neck Cancer", "GastroEsophageal Cancer" ], "interventions": [ { "name": "FT536", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Avelumab", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Nivolumab", "type": "COMBINATION_PRODUCT" }, { "name": "Atezolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Trastuzumab", "type": "COMBINATION_PRODUCT" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" }, { "name": "Amivantamab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-05-31", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-15T10:52:35.433Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05395052" }, { "nct_id": "NCT00525148", "title": "LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "BIBW 2992", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 129, "start_date": "2007-08", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-09-16", "last_synced_at": "2026-10-15T10:52:35.433Z", "location_count": 23, "location_summary": "Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00525148" }, { "nct_id": "NCT03128008", "title": "Locally Advanced NSCLC Hyperfractionated RT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non Small Cell Lung (NSCLC)" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Daily hyperfractionated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-12-07", "completion_date": "2021-01-27", "has_results": true, "last_update_posted_date": "2021-05-28", "last_synced_at": "2026-10-15T10:52:35.433Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03128008" }, { "nct_id": "NCT02983578", "title": "Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Mismatch Repair Deficiency", "Refractory Colorectal Carcinoma", "Refractory Lung Carcinoma", "Refractory Pancreatic Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-03-02", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-10-15T10:52:35.433Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983578" }, { "nct_id": "NCT03735628", "title": "An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "Copanlisib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2018-10-17", "completion_date": "2022-10-13", "has_results": false, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-10-15T10:52:35.433Z", "location_count": 5, "location_summary": "Beverly Hills, California • Los Angeles, California • Denver, Colorado + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Canton", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03735628" }, { "nct_id": "NCT02575404", "title": "GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-Small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "GR-MD-02", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2016-05-16", "completion_date": "2022-10-10", "has_results": false, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-15T10:52:35.433Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02575404" }, { "nct_id": "NCT01998126", "title": "Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2013-12-02", "completion_date": "2018-03-29", "has_results": false, "last_update_posted_date": "2018-04-02", "last_synced_at": "2026-10-15T10:52:35.433Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998126" }, { "nct_id": "NCT03517332", "title": "Circulating Tumor DNA Exposure in Peripheral Blood", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Pancreatic Adenocarcinoma", "Gastric Cancer", "Hepatocellular Carcinoma", "Non-small Cell Lung Cancer", "Bladder Cancer", "Melanoma", "Ovarian Cancer", "Adrenocortical Cancer", "Breast Cancer", "Other Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Quantgene Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10000, "start_date": "2015-01-01", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2018-11-20", "last_synced_at": "2026-10-15T10:52:35.433Z", "location_count": 5, "location_summary": "Tucson, Arizona • Celebration, Florida • Orlando, Florida + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Celebration", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Centerville", "state": "Ohio" }, { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517332" } ] }